Search CTL/CD8+ T-Cell Epitope Database

Found 1 matching record:

Displaying record number 85

Download this epitope record as JSON.

HXB2 Location	Gag(77-85) p17(77-85) DNA(1018..1044)	Gag Epitope Map
Author Location	p17
Epitope	SLYNTVATL	Epitope Alignment
		Show epitope variants
Epitope Name	SL9
Species (MHC/HLA)	human(A2)
Immunogen	HIV-1 infection
Patient MHC/HLA	9300868: A*02, A*24, B*27, B*35; 003: A*02, A*03, B*07, B*51
Experimental methods	Chromium-release assay, HLA binding
Keywords	binding affinity

Notes

• Naturally occurring variants of this epitope escaped killing and acted as potent antagonists at low concentrations, but as agonists at high concentrations.
• The following variants were found in HIV-1 infected patients who mounted a strong response against this epitope: --F------, --F----V-, --S------, -SF------, --L------, -----I---, -----I-V-, --F--I---, --F--I-V-, --F-A----
• All variants bound to A*02 with at least half the affinity of SLYNTVATL except the triple mutant: --F--I-V-
• Antagonism could be observed at low concentrations, abrogating lysis at an antagonist:agonist ratio of 1:10 -- the antagonism was observed in one SLYNTVATL-specific CTL line, 9300868 but not another, 003.

References

Sewell1997 A. K. Sewell, G. C. Harcourt, P. J. Goulder, D. A. Price, and R. E. Phillips. Antagonism of Cytotoxic T Lymphocyte-Mediated Lysis by Natural HIV-1 Altered Peptide Ligands Requires Simultaneous Presentation of Agonist and Antagonist Peptides. Eur. J. Immunol., 27:2323-2329, 1997. PubMed ID: 9341776. Show all entries for this paper.